27 April 2023 - - The first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, for the treatment of generalized anxiety disorder, Sunovion Pharmaceuticals Inc and Otsuka Pharmaceutical Development & Commercialization, Inc. said.

In addition to GAD, ulotaront is being investigated in late-stage clinical studies for the treatment of schizophrenia and for the adjunctive treatment of major depressive disorder.

The multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-dose study will evaluate ulotaront's efficacy and safety in people living with GAD. A total of 434 patients are expected to be randomized into two treatment groups, receiving either ulotaront (SEP-363856, 50–75 mg/day) or placebo in a 1: 1 ratio for eight weeks.

The primary endpoint is reduced anxiety symptoms, as measured by a change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) total score, compared to placebo at Week 8.

Ulotaront, a TAAR1 agonist with 5-HT1A agonist activity, is currently under investigation for the treatment of schizophrenia, generalized anxiety disorder and the adjunctive treatment of major depressive disorder with additional indications under consideration.

Ulotaront was granted Breakthrough Therapy Designation by the US Food and Drug Administration for the treatment of schizophrenia in 2019.

Ulotaront is the first TAAR1 agonist to enter Phase 3 clinical studies in adults and adolescents (13 to 17 years) with schizophrenia. Ulotaront is also the first TAAR1 agonist to enter Phase 2/3 clinical studies in GAD and the adjunctive treatment of MDD.

Ulotaront is being jointly developed and commercialized as part of a collaboration between Otsuka Pharmaceutical Co., Ltd, Sunovion, and its parent company Sumitomo Pharma Co., Ltd. Sunovion discovered ulotaront in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms.

An estimated 374m people globally are impacted by anxiety disorders.3 Generalized anxiety disorder is a type of anxiety disorder characterized by excessive anxiety and worry about a variety of events or activities (e.g., work or school performance) that occurs more days than not, for at least six months.

People with GAD find it difficult to control their worry, feel restless or on edge, fatigued, have difficulty concentrating, feel irritable or have trouble falling or staying asleep.

GAD may cause impairment in social and occupational functioning, or other areas of daily life and may be brought on or exacerbated by stressful life events.

Roughly 20 m people in the US will experience GAD at some point in their lifetime.

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions.

Sunovion has charted new paths to life-transforming treatments that reflect an ongoing commitment to research and development for people living with serious psychiatric and neurological conditions.

Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Pharma Co., Ltd. Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, is a wholly-owned direct subsidiary of Sunovion Pharmaceuticals Inc.

As announced on April 3, Sunovion will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma, Inc., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sumitomo Pharma Oncology, Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023.

Sumitomo Pharma is among the top-10 listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including Japan, the US, China, and other Asian countries.

Sumitomo Pharma aims to create innovative pharmaceutical products in the Psychiatry & Neurology area, the Oncology area and Regenerative medicine/Cell therapy field, which have been designated as the focus therapeutic areas.

Today, Sumitomo Pharma has about 7,000 employees worldwide.

Otsuka is a global healthcare company. In pharmaceuticals, Otsuka is in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue.